Kelvin Le

Mr. Kelvin Le


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2024 in Pharmacy
Verified
Journal Article
Open access
PDF file
KLKhang Duy Ricky Le
Khang Duy Ricky Le
KLKelvin Le
Kelvin Le
FFFelicia Foo
Felicia Foo
Background: Obstructive sleep apnoea (OSA) and associated hypopnoea syndromes are chronic conditions of sleep-disordered breathing with significant sequelae if poorly managed, including hypertension, cardiovascular disease, metabolic syndrome and increased mortality. Glucagon-like peptide 1 receptor agonists (GLP-1RA) have recently garnered significant interest as a potential therapeutic, attributed to their durable effects in weight loss and glycaemic control in metabolic syndromes, such as obesity and type 2 diabetes mellitus. This has led to significant investment into companies that produce these medications and divestment from traditional gold standard methods of OSA management such as continuous positive airway pressure machines. Despite these sentiments, the impacts of these medications on OSA outcomes are poorly characterised, with no high-quality evidence at this stage to support this hypothesis. This scoping review therefore aims to address the research question of whether GLP-1RAs lead to a direct improvement in OSA and associated hypopnoea syndromes. Methods: A scoping review was performed following a computer-assisted search of Medline, Embase and Cochrane Central databases. Papers that evaluated the use of GLP-1RA medications related to sleep-disordered breathing, OSA or other sleep-related apnoeic or hypopnoeic syndromes were included. Results: Literature search and evaluation identified 9 articles that were eligible for inclusion. Of these, 1 was a study protocol, 1 was a case report, 1 was an abstract of a randomised controlled trial (RCT), 1 was a non-randomised clinical trial and the remaining 5 were randomised clinical trials of variable rigour. All studies evaluated the outcomes of GLP-1RAs in patients with diagnosed OSA or symptoms suggestive of this condition. Conclusion: This scoping review identified early evidence to suggest that GLP-1RAs may improve OSA as defined by reduction in apnoea-hypopnoea index (AHI). This evidence is however conflicting due to contradicting results demonstrated from other studies. Overall, these medications were tolerated well, with minor gastrointestinal side-effects reported in some cases. Of all included studies, the quality of evidence was low, with short lengths of follow-up to identify durable effects of these medications on OSA outcomes and identify adverse events. More rigorous, RCTs with sufficient length of follow-up are required before consideration of formalising these medications into OSA treatment guidelines, frameworks and policies are warranted.

5 June 2024 in Genes
Verified
Journal Article
Open access
PDF file
GAGabrielle L. Adler
Gabrielle L. Adler
KLKelvin Le
Kelvin Le
YFYuhong Fu
Yuhong Fu
WKWoojin Kim
Woojin Kim
Human endogenous retroviruses (HERVs) are DNA transposable elements that have integrated into the human genome via an ancestral germline infection. The potential importance of HERVs is underscored by the fact that they comprise approximately 8% of the human genome. HERVs have been implicated in the pathogenesis of neurodegenerative diseases, a group of CNS diseases characterized by a progressive loss of structure and function of neurons, resulting in cell death and multiple physiological dysfunctions. Much evidence indicates that HERVs are initiators or drivers of neurodegenerative processes in multiple sclerosis and amyotrophic lateral sclerosis, and clinical trials have been designed to target HERVs. In recent years, the role of HERVs has been explored in other major neurodegenerative diseases, including frontotemporal dementia, Alzheimer’s disease and Parkinson’s disease, with some interesting discoveries. This review summarizes and evaluates the past and current research on HERVs in neurodegenerative diseases. It discusses the potential role of HERVs in disease manifestation and neurodegeneration. It critically reviews antiretroviral strategies used in the therapeutic intervention of neurodegenerative diseases.

6 April 2024 in Trauma Care
Verified
Journal Article
Open access
PDF file
KLKhang Duy Ricky Le
Khang Duy Ricky Le
KLKelvin Le
Kelvin Le
ASAbdullah Shahzad
Abdullah Shahzad
SLSu Jin Lee
Su Jin Lee
(1) Background: Patients who experience acute traumatic injury requiring hospitalisation represent a vulnerable population. The trauma patient often experiences multi-system injuries and complex physiology. Additionally, there are complex socio-ecological issues that impact the care and outcomes of trauma patients. Of interest, culturally and linguistically diverse populations with language barriers experience worse outcomes in trauma settings. This scoping review evaluates the current evidence on language barriers in this population and the influences on outcomes for trauma patients. (2) Methods: A scoping review was performed following a computer-assisted search of the Medline, Embase and Cochrane Central databases. Papers that evaluated the impact of the language barrier in culturally and linguistically diverse populations and outcomes in acute trauma settings were included. (3) Results: A literature search identified eight articles that were eligible for inclusion. Overall, there was no robust evidence to suggest that such populations were disadvantaged in terms of length of hospital stay and overall mortality. However, studies did identify that these populations were at higher risk of disability and poor mental health outcomes, experienced communication barriers more often and had lower social functioning. (4) Conclusions: This scoping review demonstrates that individuals admitted due to trauma who are from culturally and linguistically diverse backgrounds experience more significant disadvantages concerning psychological and functional outcomes. It is posited this is due to their inability to communicate their complex needs in trauma, however more robust and rigorous research is required to better characterise this effect.

12 October 2024 in Emergency Care and Medicine
Verified
Journal Article
Open access
PDF file
KLKelvin Le
Kelvin Le
JCJiahang Chen
Jiahang Chen
DMDeon Mai
Deon Mai
KLKhang Duy Ricky Le
Khang Duy Ricky Le
Large Language Models (LLMs) are becoming increasingly adopted in various industries worldwide. In particular, there is emerging research assessing the reliability of LLMs, such as ChatGPT, in performing triaging decisions in emergent settings. A unique aspect of emergency triaging is the process of trauma triaging. This process requires judicious consideration of mechanism of injury, severity of injury, patient stability, logistics of location and type of transport in order to ensure trauma patients have access to appropriate and timely trauma care. Current issues of overtriage and undertriage highlight the potential for the use of LLMs as a complementary tool to assist in more accurate triaging of the trauma patient. Despite this, there remains a gap in the literature surrounding the utility of LLMs in the trauma triaging process. This narrative review explores the current evidence for the potential for implementation of LLMs in trauma triaging. Overall, the literature highlights multifaceted applications of LLMs, especially in emergency trauma settings, albeit with clear limitations and ethical considerations, such as artificial hallucinations, biased outputs and data privacy issues. There remains room for more rigorous research into refining the consistency and capabilities of LLMs, ensuring their effective integration in real-world trauma triaging to improve patient outcomes and resource utilisation.

31 August 2024 in Medicina
Verified
Journal Article
Open access
PDF file
KLKelvin Le
Kelvin Le
JMJames Norton Marchant
James Norton Marchant
KLKhang Duy Ricky Le
Khang Duy Ricky Le
Background and Objectives: Conventional radiotherapies used in the current management of rectal cancer commonly cause iatrogenic radiotoxicity. Proton beam therapy has emerged as an alternative to conventional radiotherapy with the aim of improving tumour control and reducing off-set radiation exposure to surrounding tissue. However, the real-world treatment and oncological outcomes associated with the use of proton beam therapy in rectal cancer remain poorly characterised. This systematic review seeks to evaluate the radiation dosages and safety of proton beam therapy compared to conventional radiotherapy in patients with non-metastatic rectal cancer. Materials and Methods: A computer-assisted search was performed on the Medline, Embase and Cochrane Central databases. Studies that evaluated the adverse effects and oncological outcomes of proton beam therapy and conventional radiotherapy in adult patients with non-metastatic rectal cancer were included. Results: Eight studies were included in this review. There was insufficient evidence to determine the adverse treatment outcomes of proton beam therapy versus conventional radiotherapy. No current studies assessed radiotoxicities nor oncological outcomes. Pooled dosimetric comparisons between proton beam therapy and various conventional radiotherapies were associated with reduced radiation exposure to the pelvis, bowel and bladder. Conclusions: This systematic review demonstrates a significant paucity of evidence in the current literature surrounding adverse effects and oncological outcomes related to proton beam therapy compared to conventional radiotherapy for non-metastatic rectal cancer. Pooled analyses of dosimetric studies highlight greater predicted radiation-sparing effects with proton beam therapy in this setting. This evidence, however, is based on evidence at a moderate risk of bias and clinical heterogeneity. Overall, more robust, prospective clinical trials are required.

13 March 2026 in Surgeries
Verified
Journal Article
Open access
PDF file
AJAlexandra Jolley
Alexandra Jolley
KLKelvin Le
Kelvin Le
CDCharlotte Deng
Charlotte Deng
KLKhang Duy Ricky Le
Khang Duy Ricky Le
Background: Oesophageal cancer is a diagnosis carrying significant morbidity and mortality. Gold standard treatment is resection; however, this requires a complex operation. Despite progression to minimally invasive approaches, post-operative pain is a significant issue. Methadone is emerging as an additive intraoperative analgesic across specialities, with a single intra-operative dose seen to improve post-operative pain and reduce post-operative opioid use. This is promising for oesophagectomy patients, where pain is a significant issue; however, it remains poorly characterised. Aim: This paper aimed to assess the literature surrounding intra-operative methadone (IOM) in oesophagectomy, then broadly consider related evidence to consider how it may be applicable to patients undergoing oesophagectomy for oesophageal cancer. Methods: The search assessed existing evidence for efficacy and safety of IOM for patients undergoing oesophagectomy for oesophageal cancer. Of 1856 studies, only one fit inclusion criteria. Following this, the search was broadened to assess IOM use in related surgical contexts, deriving applicability to oesophagectomy. Results: There is very limited evidence for IOM use in oesophagectomy. Several papers explore its use in other intraabdominal and intrathoracic procedures. This evidence may be leveraged for oesophagectomy patients. There remain several safety concerns, most notably respiratory and cardiac risks. Further, several knowledge gaps remain. Conclusions: Overall, IOM represents a promising analgesic option. Unfortunately, current evidence is limited, predominantly derived from non-generalisable studies. This paper provides an up-to-date review of evidence, highlighting clear gaps. It is clear oesophagectomy patients are a vulnerable group who would benefit from improved pain and post-operative quality of life. As such, further focused research should be done to evaluate the role of IOM in oesophagectomy for oesophageal cancer.